Abbvie Inc(ABBV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
AI-drawn chart patterns are for reference only.
Full metrics table
| Index | S&P 500, RUI | P/E | 50.68 | EPS (ttm) | 5.81 | Insider Own | - | Shs Outstand | 1.77B | Perf Week | 2.15% |
| Market Cap | 520.47B | Forward P/E | 18.11 | EPS next Y | 16.14% | Insider Trans | - | Shs Float | 1.77B | Perf Month | 3.87% |
| Enterprise Value | 590.65B | PEG | 0.83 | EPS next Q | 3.89 | Inst Own | 78.34% | Short Float | 0.9% | Perf Quarter | 18.03% |
| Income | 10.30B | P/S | 7.88 | EPS this Y | 40.01% | Inst Trans | 0.89% | Short Ratio | 3.3 | Perf Half Y | 39.7% |
| Sales | 66.01B | P/B | - | EPS next 5Y | 21.77% | ROA | 7.31% | Short Interest | 15.81M | Perf YTD | 28.87% |
| Book/sh | -2.59 | P/C | 48.31 | EPS past 3/5Y | -29.11% -2.81% | ROE | 15221.82% | 52W High | -2.8% ($302.93) | Perf Year | 26.25% |
| Cash/sh | 6.1 | P/FCF | 27.58 | Sales past 3/5Y | 1.75% 5.95% | ROIC | 15.22% | 52W Low | 54.36% ($190.75) | Perf 3Y | 112.46% |
| Dividend Est. | $6.88 (2.33%) | EV/EBITDA | 18.69 | EPS Y/Y TTM | 338.08% | Gross Margin | 73.72% | Volatility(W/M) | 2.17% 2.42% | Perf 5Y | 151.73% |
| Dividend TTM | 6.92 | EV/Sales | 8.95 | Sales Y/Y TTM | 10.68% | Oper. Margin | 36.18% | ATR (14) | 7.11 | Perf 10Y | 366.64% |
| Dividend Ex-Date | 2027/1/15 | Quick Ratio | 0.75 | EPS Q/Q | 2289.73% | Profit Margin | 15.6% | RSI (14) | 62.01 | Recom | 1.57 |
| Dividend Gr. 3/5Y | 5.21% 6.56% | Current Ratio | 0.87 | Sales Q/Q | 10.32% | SMA20 | 1.83% ($289.16) | Beta | 0.19 | Target Price | $314.81 |
| Payout | 281.66% | Debt/Eq | - | Earnings | 2026/10/30 | SMA50 | 7.15% ($274.8) | Rel Volume | 1.01 | Prev Close | $294.98 |
| Employees | 57000 | LT Debt/Eq | - | EPS/Sales Surpr. | 2.51% 0.51% | SMA200 | 22.48% ($240.41) | Avg Volume(3M) | 4.79M | Price | $294.45 |
| IPO | 2012/12/10 | Option/Short | Yes/Yes | Trades | 47346 | Volume | 4,826,825 | Change | -0.18% |
AbbVie is a global large-cap pharmaceutical company with strengths in immunology, neuroscience, oncology, and aesthetic medicine. Since spinning off from Abbott Laboratories and listing as an independent company in 2013, it has rapidly diversified away from its reliance on Humira, reshaping its portfolio into a diverse lineup of growth products such as Skyrizi, Rinvoq, Botox, and Vraylar to become a megacap healthcare player.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded about as much as usual. That is 101% of its average volume.
ABBV makes money exceptionally well
Of every $100 in sales, $36.18 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +40.0% this year.
Tap to view numbers
However, it looks expensive
For a company expected to earn $100 next year, you would pay $1,811. Peers typically go for $1,582. It is about in line with its own 5-year average.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +151.7%. The S&P 500 did +62% over the same period.
Tap to view numbers
Dividends are more than it earns
It pays out 282% of what it earns.
Tap to view numbers
Ownership looks stable
Institutions hold 78.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #3 of 21 in the industry
Based on market cap of $520B.
Earnings Analysis · 7/31 AbbVie ($ABBV) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat Expectations, Full-Year Guidance Trimmed Slightly Investing Guides · 4/11 The Complete 2026 Guide to U.S. Dividend Aristocrats Investing Guides · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is ABBV?
ABBV belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of ABBV?
The market cap of ABBV is approximately $520.5B, ranking 25 within its sector.
Does ABBV pay dividends?
ABBV has a dividend yield of approximately 2.33%, with an annual dividend of $6.88.
What is the P/E ratio of ABBV?
ABBV has a P/E ratio of approximately 50.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ABBV?
ABBV has recorded a 52-week high of $302.93 and a low of $190.75.
